Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
155.66
-1.64 (-1.04%)
At close: May 8, 2025, 4:00 PM
155.86
+0.20 (0.13%)
After-hours: May 8, 2025, 7:02 PM EDT
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $21.89B in the quarter ending March 30, 2025, with 2.39% growth. This brings the company's revenue in the last twelve months to $89.33B, up 4.30% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$89.33B
Revenue Growth
+4.30%
P/S Ratio
4.19
Revenue / Employee
$646,857
Employees
138,100
Market Cap
374.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
JNJ News
- 13 hours ago - Jury Orders Johnson & Johnson to Pay $3 Million in Mesothelioma Death of New Orleans Woman - Business Wire
- 17 hours ago - Johnson & Johnson expands efforts to champion the nursing workforce globally - Business Wire
- 1 day ago - Dividend Hikes Offer Optimism Amid Tariff Turmoil - Seeking Alpha
- 3 days ago - Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms - CNBC
- 3 days ago - TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks - PRNewsWire
- 3 days ago - TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years - PRNewsWire
- 5 days ago - Dogs Of The Dow Chase May's 'Safer' Buy - Seeking Alpha
- 7 days ago - J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports - Reuters